Peptide Education Resource
Peptides are short chains of amino acids — the same building blocks as proteins, just smaller. Many of the peptides studied by researchers are identical or nearly identical to signals your own body produces. This resource explains what they are, how researchers think they work, and what the science shows so far.
The Basics
Think of amino acids as individual letters. Proteins are long novels. Peptides are short sentences — specific enough to carry a precise message, small enough to deliver it efficiently.
Your body is already fluent in peptide language. Hormones like insulin, oxytocin, and many signaling molecules are peptides. When a peptide reaches a receptor on a cell, it’s like a key in a lock — it triggers a specific response without affecting every other system in the body.
Researchers study peptides because of this specificity. Unlike broad-acting drugs, peptides tend to trigger targeted pathways, which is why so many are under active investigation for wellness, recovery, metabolic health, and longevity.
Most research peptides are administered by subcutaneous injection because the digestive system would break them down before they reach the bloodstream.
Before you buy anything
The “US-made” claims. The purity numbers. The vial that weighs more than the label says. Our sourcing guide explains the global supply chain reality, what third-party testing actually means, and what questions to ask any vendor before you trust them.
Section 01 — Growth Hormone
Growth hormone does not work in isolation. It is the centerpiece of a cascading chain of signals that starts deep in your brain and ends at nearly every cell in your body. Understanding the chain helps clarify why researchers are so interested in stimulating it naturally.
It starts in the hypothalamus, a small region at the base of your brain that acts as your body’s master control center. When conditions are right — during deep sleep, after exercise, or when blood sugar is low — the hypothalamus releases Growth Hormone Releasing Hormone (GHRH).
GHRH travels a short distance to the pituitary gland, which responds by secreting Growth Hormone (GH) into the bloodstream. GH itself does not do most of the heavy lifting directly. Instead, it travels to the liver, which converts it into Insulin-like Growth Factor 1 (IGF-1) — the molecule responsible for most of GH’s anabolic and regenerative effects.
Peptides like CJC-1295, Ipamorelin, Sermorelin, and Tesamorelin signal the pituitary to release more of your own GH. Your body’s feedback systems remain intact, which is why researchers consider this the most physiologically conservative approach.
Synthetic human growth hormone is administered directly, bypassing the hypothalamus-pituitary step entirely. This can suppress the body’s own production over time.
Administering IGF-1 directly bypasses both the pituitary and liver steps. Research has examined both IGF-1 LR3 and des-IGF-1 variants. Because it acts on insulin receptors, metabolic monitoring is a key consideration in studies using this approach.
GHRH ANALOGUE
A modified version of GHRH that binds to albumin in the blood, dramatically extending its half-life from minutes to days. This allows for less frequent dosing while maintaining elevated GH pulses.
GHRP / GHRELIN MIMETIC
Ipamorelin mimics ghrelin (the “hunger hormone”) and binds ghrelin receptors on the pituitary, causing a clean GH pulse. It is considered highly selective — research shows minimal effect on cortisol or prolactin compared to other GHRPs.
GHRH ANALOGUE · FIRST-GENERATION
Sermorelin is a synthetic analogue of the first 29 amino acids of natural GHRH — the biologically active fragment responsible for pituitary stimulation. It was one of the earliest GHRH analogues studied clinically, and has a long research history in both pediatric GH deficiency and adult anti-aging contexts. Because it works upstream by stimulating the pituitary’s own GH release, the body’s natural feedback loop (somatostatin inhibition) remains fully intact, which researchers consider an important safety characteristic.
GHRH ANALOGUE · STABILIZED FORM
Tesamorelin is a stabilized form of full-length GHRH (44 amino acids) modified with a trans-3-hexenoic acid group that extends its half-life while preserving the complete natural GHRH sequence. It is notable for being the only GHRH analogue to receive FDA approval — for visceral adiposity reduction in HIV-associated lipodystrophy — giving it an unusually strong clinical evidence base compared to most research peptides. Studies have consistently shown significant reduction in visceral fat, improved IGF-1 levels, and favorable effects on cognitive function in older adults.
Research into the GH axis spans decades and covers a wide range of physiological effects.
GH directly stimulates lipolysis — the breakdown of stored fat for energy — particularly visceral fat around the abdomen. This effect is independent of caloric restriction and occurs even without changes to diet.
The largest natural GH pulse occurs during the first cycle of slow-wave (deep) sleep. Secretagogue peptides, particularly Ipamorelin and Sermorelin dosed in the evening, have been associated with improved sleep architecture in research settings — more time in slow-wave sleep and enhanced overnight recovery.
IGF-1 is a primary driver of muscle protein synthesis and satellite cell activation — the process by which muscles repair microtears after exercise. Studies show improved recovery time and reduced delayed-onset muscle soreness.
GH and IGF-1 stimulate osteoblast activity (bone-building cells) and are well-established in GH deficiency treatment protocols for maintaining bone mineral density.
IGF-1 receptors are expressed in hair follicles, skin fibroblasts, and nail matrix cells. Elevated IGF-1 is associated with increased collagen synthesis, improved skin thickness and elasticity, and enhanced hair follicle cycling.
Both GH and IGF-1 cross the blood-brain barrier. Research links adequate IGF-1 levels to better cognitive performance, neurogenesis in the hippocampus, and reduced neuroinflammation with aging.
Testosterone and IGF-1 work through overlapping but distinct pathways, and each enhances the other’s effects. Testosterone upregulates GH receptors in the liver, meaning more of the GH you produce gets converted to IGF-1. Meanwhile, IGF-1 supports Leydig cell function in the testes, which is involved in testosterone production. In research contexts, optimizing the GH axis alongside testosterone replacement has been associated with significantly greater lean mass and fat loss outcomes than either approach alone — an additive effect that has made this combination a frequent subject of study in aging and body composition research.
Section 02 — Metabolic Peptides
GLP stands for Glucagon-Like Peptide. These are hormones your gut releases in response to food. Researchers have developed peptide analogues that mimic and extend these signals — with profound effects on blood sugar, appetite, and metabolic health.
GLP-1 is released from your intestinal L-cells within minutes of eating. It has two primary jobs: tell the pancreas to release insulin (to manage blood sugar), and tell the brain to stop eating. It also slows gastric emptying — food moves through your stomach more slowly, prolonging the feeling of fullness.
The challenge is that natural GLP-1 is degraded in the bloodstream within 2–5 minutes. Research peptides are engineered to resist this degradation, extending their activity from minutes to days or weeks.
GLP-2 is co-released alongside GLP-1 but targets a completely different system: the intestinal lining. It stimulates the growth and repair of gut epithelial cells, reduces intestinal permeability (the “leaky gut” problem), and has been studied in conditions like Crohn’s disease and short bowel syndrome.
Some researchers are exploring the combination of GLP-1 and GLP-2 activity for metabolic benefit alongside gut health — a dual approach not possible with any single approved medication.
| Peptide | Receptor Targets | Primary Research Areas | What Studies Have Used | Key Distinction |
|---|---|---|---|---|
| Semaglutide | GLP-1R | Type 2 diabetes, obesity, cardiovascular risk, NAFLD | 0.25–2.4 mg/week subcutaneous | Most studied; cardiovascular outcome data; once-weekly dosing |
| Tirzepatide | GLP-1R + GIPR | Obesity, insulin resistance, lipid profiles | 2.5–15 mg/week subcutaneous | Dual agonism produces additive fat loss vs. GLP-1 alone; improved lipid panels in trials |
| Retatrutide | GLP-1R + GIPR + GCGR | Obesity, metabolic syndrome, NASH | 1–12 mg/week subcutaneous — Phase 2/3 trials | Triple agonism; glucagon receptor activation increases energy expenditure; most aggressive body recomposition in trials |
Each additional receptor target addresses a different piece of the metabolic puzzle. GLP-1 handles insulin and appetite. GIP (glucose-dependent insulinotropic polypeptide) improves fat storage regulation and has additive effects on insulin secretion. Glucagon receptor activation increases energy expenditure at rest. The triple agonist Retatrutide is being studied because hitting all three simultaneously may produce metabolic changes that no single-target approach can match — essentially attacking different failure modes of metabolism in parallel.
Section 03 — Repair & Regeneration
BPC-157, TB-500, and GHK-Cu are three of the most-studied repair and regeneration peptides in research literature. Each works through a distinct mechanism. Together, they address soft tissue healing from multiple angles simultaneously.
BODY PROTECTION COMPOUND — 15 AMINO ACIDS
BPC-157 is derived from a protective protein found in gastric juice. It has been extensively studied in animal models of injury, where it consistently accelerates healing of tendons, ligaments, muscle, bone, and gut tissue. Its primary mechanism appears to involve upregulation of growth factors at the injury site — particularly VEGF (vascular endothelial growth factor), which drives new blood vessel formation.
Notably, BPC-157 shows effects when administered both locally (near the injury) and systemically, suggesting it may act through central as well as local pathways. It is also one of the most-studied peptides for gut health, with research covering colitis, gastric ulcers, and intestinal permeability.
THYMOSIN BETA-4 ANALOGUE — SYNTHETIC FRAGMENT
TB-500 is a synthetic fragment of Thymosin Beta-4, a protein naturally present in high concentrations at wound sites. Its primary mechanism is the regulation of actin — a structural protein essential for cell migration. By freeing up actin and enabling rapid cell movement toward injury sites, TB-500 accelerates the arrival of repair cells.
TB-500’s distinguishing feature is its systemic mobility: it distributes widely through the body regardless of injection site, making it effective for hard-to-reach injuries. It also has well-documented anti-inflammatory properties and has been studied for cardiac repair after ischemia.
BPC-157 + TB-500
Named for the near-instantaneous healing ability of the Marvel character, the Wolverine stack combines BPC-157 and TB-500 to address soft tissue injury from two mechanistic angles. BPC-157 drives local growth factor upregulation and angiogenesis at the injury site, while TB-500 handles the systemic cell migration piece — mobilizing repair cells and getting them there faster. Together they cover both the “build the scaffold” and “get the workers there” parts of tissue repair.
BPC-157 is primarily local — it stimulates repair at and near the site of administration. TB-500 is primarily systemic — it distributes widely and recruits cells from remote locations. The combination means you are not choosing between local precision and systemic reach; you are getting both. The mechanistic complementarity here is unusually clean — there is little overlap in their pathways, so the combination is largely additive rather than redundant.
GLYCINE-HISTIDINE-LYSINE COPPER COMPLEX
GHK-Cu is a naturally occurring copper complex found in human plasma, urine, and saliva. Its plasma levels decline sharply with age — from roughly 200 ng/mL at age 20 to under 80 ng/mL after age 60. Research has identified it as a potent activator of tissue remodeling, collagen synthesis, and antioxidant defenses.
What makes GHK-Cu unusual is the breadth of its effects. Gene expression studies show it modulates over 4,000 human genes, including those involved in collagen and glycosaminoglycan synthesis, anti-inflammatory pathways, antioxidant enzyme production, and nerve regeneration.
BPC-157 + TB-500 + GHK-Cu
GLOW adds GHK-Cu to the Wolverine foundation, shifting the stack’s profile from pure injury repair toward full-spectrum tissue regeneration and aesthetic renewal. While Wolverine handles the structural repair — tendons, muscle, ligaments — GHK-Cu adds a layer of collagen remodeling, skin quality improvement, and antioxidant gene activation that extends the stack’s benefits to connective tissue quality, skin, and hair.
BPC-157 brings the blood supply (angiogenesis). TB-500 brings the cells (migration and actin regulation). GHK-Cu brings the blueprint — it upregulates the genes that tell cells what kind of tissue to build, driving collagen, elastin, and glycosaminoglycan production. Together they represent the three pillars of tissue repair: vascular supply, cellular recruitment, and extracellular matrix construction.
Section 04 — Cellular Energy
Mitochondria are the power plants of every cell — they convert food and oxygen into ATP, the energy currency your body runs on. Mitochondrial decline is considered one of the central drivers of aging. These peptides and compounds target it from three complementary angles.
SZETO-SCHILLER PEPTIDE · 4 AMINO ACIDS
SS-31 is a cell-permeable tetrapeptide that specifically targets the inner mitochondrial membrane, where it binds to cardiolipin — a unique phospholipid that acts as the structural scaffold for the electron transport chain. As we age, cardiolipin becomes oxidized and damaged, causing the electron transport chain to become inefficient, producing more reactive oxygen species (ROS) and less ATP.
SS-31 works by protecting and reorganizing cardiolipin, essentially restoring the mitochondria’s inner architecture. Clinical trials have studied it in heart failure with preserved ejection fraction, age-related muscle loss (sarcopenia), and kidney disease.
MITOCHONDRIAL ORF OF 12S rRNA TYPE-C
MOTS-c is remarkable for a specific reason: it is encoded in mitochondrial DNA, not nuclear DNA. It is a peptide that mitochondria themselves produce as a distress signal. When mitochondria are under stress, MOTS-c is released, travels to the nucleus, and activates AMPK — the master metabolic regulator that promotes fat burning, glucose uptake, and mitochondrial biogenesis (creation of new mitochondria).
Plasma MOTS-c levels naturally decline with age. Research has examined it in exercise physiology, insulin sensitivity, obesity, and aging — including human studies showing correlations between MOTS-c levels and longevity.
NICOTINAMIDE ADENINE DINUCLEOTIDE
NAD+ is not a peptide — it is a coenzyme found in every cell of your body. It is included here because it is the essential fuel for the mitochondrial stack. NAD+ acts as an electron shuttle in the electron transport chain, and it is the required co-factor for sirtuin proteins, which regulate DNA repair, inflammation, and cellular aging. By age 50, most people have lost roughly half their NAD+ levels.
Direct NAD+ supplementation has poor bioavailability. Research focuses on precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — which the body converts to NAD+. IV NAD+ achieves higher plasma levels than oral precursors and has been studied in addiction recovery, cognitive decline, and athletic performance.
SS-31 + MOTS-c + NAD+
These three compounds target mitochondrial health at different levels of the same system. SS-31 works at the physical structure — protecting and repairing the membrane architecture that makes efficient ATP production possible. MOTS-c works at the signaling level — activating the cellular programs that create new mitochondria and optimize metabolic pathways. NAD+ works at the fuel level — replenishing the coenzyme that the entire electron transport chain depends on.
If your mitochondria were a factory: SS-31 repairs the machinery, MOTS-c hires new workers and upgrades the processes, and NAD+ keeps the power on. None of them do the same job. Each is necessary but not sufficient on its own. Together they address the three ways mitochondrial function degrades with age: structural damage, reduced biogenesis, and depleted metabolic cofactors.
These stacks are not mutually exclusive. Research literature increasingly examines combinations, particularly in longevity, anti-aging, and performance contexts.
| Combination | Rationale | Primary Area of Interest |
|---|---|---|
| GH Axis + Mito Stack | IGF-1 promotes mitochondrial biogenesis; MOTS-c improves insulin sensitivity to support GH’s metabolic effects | Body composition, energy, aging |
| GLP + GH Axis | GLP-1 agonists reduce visceral fat; GH axis peptides preserve muscle during caloric deficit — addressing both sides of body recomposition | Weight loss with muscle retention |
| GLOW + GH Axis | GHK-Cu drives collagen synthesis; IGF-1 activates the same fibroblast pathways — additive effect on skin, hair, and connective tissue | Aesthetic regeneration, connective tissue |
| Full longevity protocol | GH axis + Mito stack + GLOW + GLP represents the full spectrum of aging’s primary drivers addressed in parallel | Comprehensive healthspan research |